Gemcitabine remains a mainstay in cancer treatment, but scientists are exploring how it can work alongside cutting-edge therapies. While some drug combinations have failed to improve outcomes, other ...

FDA expands Alpha DaRT IMPACT trial to 40 patients, adding gemcitabine and nab-paclitaxel cohort in pancreatic cancer.

Among 40 patients treated with daraxonrasib plus gemcitabine and nab-paclitaxel, the confirmed objective response rate (ORR) ...

While the method may sound unfamiliar, it has been clinically validated for decades and remains central to preventing ...

IDE supplement expands trial to the other primary standard-of-care chemotherapy for pancreatic cancer patients, alongside mFOLFIRINOX -- IDE ...

The 2026 ASCO Annual Meeting will be held May 29 – June 2, 2026, in Chicago, Illinois, with the online publication of the abstract scheduled for May 21, 2026, at 5:00 P.M. ET.

A drug that helps the immune system find cancer cells also helps patients avoid having their bladders surgically removed ...

A drug that helps the immune system find cancer cells also helps patients avoid having their bladders surgically removed (cystectomy), a new study shows.

In this study, researchers aimed to examine survival outcomes with elraglusib plus chemotherapy compared to chemotherapy alone in untreated mPDAC.

The FDA has granted a priority review to the supplemental Biologics License Application for enfortumab/pembrolizumab to all ...

The FDA’s Priority Review designation underscores the potential of enfortumab vedotin plus pembrolizumab to address a critical unmet need in MIBC. By demonstrating improvements in survival and ...

Theriva Biologics (TOVX) stock surged 63% after Phase 2b trial data revealed VCN-01 plus chemo improved survival in ...